Fluidigm Estimates Investment in Verinata at $3.1M After Illumina Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm disclosed in its Form 10-K this week that the fair value of its investment in Verinata Health is an estimated $3.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.